Gujarat Meditech Profile
Key Indicators
- Authorised Capital ₹ 4.40 Cr
as on 24-05-2024
- Paid Up Capital ₹ 4.11 Cr
as on 24-05-2024
- Company Age 33 Year, 2 Days
- Last Filing with ROC 31 Mar 2022
- Revenue -10.91%
(FY 2017)
- Profit 672.97%
(FY 2017)
- Ebitda 175.20%
(FY 2017)
- Net Worth 0.01%
(FY 2017)
- Total Assets 8.71%
(FY 2017)
About Gujarat Meditech
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 4.40 Cr and a paid-up capital of Rs 4.11 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Gujarat Meditech Ltd. India is Pravin Deshmukh as CFO. Shewata Rathor, Ashok Rathore, Anubha Khot, and Two other members serve as directors at the Company.
- CIN/LLPIN
L74999GJ1991PLC016808
- Company No.
016808
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
17 Dec 1991
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Listed
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Gujarat Meditech?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shewata Rathor  | Managing Director | 31-Aug-2017 | Current |
| Pravin Deshmukh | CFO | 30-Sep-2015 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ashok Rathore | Whole-Time Director | 31-Aug-2017 | Current |
| Anubha Khot | Director | 10-Aug-2017 | Current |
| Pravin Deshmukh | Director and Cfo | 25-Apr-2012 | Current |
| Anand Khot | Director | 10-Aug-2017 | Current |
Financial Performance and Corporate Structure Insights of Gujarat Meditech.
Gujarat Meditech Ltd., for the financial year ended 2017, experienced significant reduction in revenue, with a 10.91% decrease. The company also saw a substantial improvement in profitability, with a 672.97% increase in profit. The company's net worth moved up by a moderate rise of 0.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gujarat Meditech?
In 2017, Gujarat Meditech had a promoter holding of 8.98% and a public holding of 91.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gujarat Meditech?
Unlock and access historical data on people associated with Gujarat Meditech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gujarat Meditech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gujarat Meditech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
